10.02.18
Hitachi Chemical Advanced Therapeutics Solutions (HCATS) has signed a three-year clinical manufacturing agreement with GSK. Under the agreement, HCATS will manufacture GSK’s SPEAR T-cell receptor therapy targeting NY-ESO-1 for the US, Canadian and European trials.
“Since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan,” said Robert A. Preti, PhD, chief executive officer and president of HCATS and general manager of the Hitachi Chemical Regenerative Medicine Business Sector. “This agreement is an exciting step for our growing global enterprise, advancing our vision to support efforts to make these transformative therapies accessible to all.”
NY-ESO is expressed across a variety of tumors including sarcomas, melanoma, multiple myeloma, bladder cancer, non-small cell lung cancer, ovarian cancer and gastro-intestinal cancers. HCATS is a US subsidiary of Hitachi Chemical Co. Ltd. that engages in contract manufacturing and development of cell-based cell and gene therapy products through its PCT Global Service Platform.
“Since becoming part of Hitachi Chemical over a year ago, we have seen increasing interest in leveraging our PCT Global Service Platform both in the United States and Japan,” said Robert A. Preti, PhD, chief executive officer and president of HCATS and general manager of the Hitachi Chemical Regenerative Medicine Business Sector. “This agreement is an exciting step for our growing global enterprise, advancing our vision to support efforts to make these transformative therapies accessible to all.”
“We are extremely proud and grateful to enter into a relationship with GSK, as it provides the opportunity to partner with an industry leader,” said Sanjin Zvonić, PhD, senior director, Business Leader, Clinical and Commercial Manufacturing of HCATS. “As with all our clients, we are committed to delivering high-quality, compliant, flexible, scalable, and cost-effective manufacturing services.”